论文部分内容阅读
肝性脑病(HE)和亚临床肝性脑病(SHE)最适宜和易得到的治疗是降低血和组织的氨浓度。临床试验已证实,L-鸟氨酸-L-天冬氨酸(OA)可有效地降低血氨。此研究进行前瞻性、随机、安慰剂对照双盲试验以确定肝硬化高血氨和轻度HE患者口服OA是否有效。 方法:每天三餐前口服溶于水的OA 6g,连续14天。病人每天的膳食含蛋白质1g/kg体重。效应变量是:禁食和餐后氨浓度、计数联系试验(NCT)时间、精神状态分级和门体循环脑病(PSE)指数。
The most appropriate and readily available treatment for hepatic encephalopathy (HE) and subclinical hepatic encephalopathy (SHE) is to reduce the blood and tissue ammonia levels. Clinical trials have confirmed that L-ornithine-L-aspartate (OA) is effective in lowering blood ammonia. In this study, a prospective, randomized, placebo-controlled, double-blind trial was conducted to determine if oral OA was effective in patients with cirrhosis and hypoalbuminemia. Methods: Oral daily dissolved in water before meals, 6g, for 14 consecutive days. The patient’s daily diet contains protein 1g / kg body weight. The effect variables were fasting and postprandial ammonia concentrations, count-linked test (NCT) time, mental status grading, and PSE index.